Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Inflammatory cytokines in major depressive disorder: A case-control study.

Cassano P, Bui E, Rogers AH, Walton ZE, Ross R, Zeng M, Nadal-Vicens M, Mischoulon D, Baker AW, Keshaviah A, Worthington J, Hoge EA, Alpert J, Fava M, Wong KK, Simon NM.

Aust N Z J Psychiatry. 2017 Jan;51(1):23-31. doi: 10.1177/0004867416652736. Epub 2016 Sep 29.

PMID:
27313138
2.

Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.

Ionescu DF, Swee MB, Pavone KJ, Taylor N, Akeju O, Baer L, Nyer M, Cassano P, Mischoulon D, Alpert JE, Brown EN, Nock MK, Fava M, Cusin C.

J Clin Psychiatry. 2016 Jun;77(6):e719-25. doi: 10.4088/JCP.15m10056.

PMID:
27232360
3.

Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis.

Cassano P, Petrie SR, Hamblin MR, Henderson TA, Iosifescu DV.

Neurophotonics. 2016 Jul;3(3):031404. doi: 10.1117/1.NPh.3.3.031404. Epub 2016 Mar 4. Review.

4.

Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.

Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, Eikermann M, Durham K, Swee MB, Chang T, Dording C, Soskin D, Kelley J, Mischoulon D, Brown EN, Fava M.

Aust N Z J Psychiatry. 2017 Jan;51(1):55-64. doi: 10.1177/0004867416631828.

PMID:
26893373
5.

Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study.

Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV.

Psychiatry J. 2015;2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19.

6.

Treatment Outcome in Depressed Latinos Predicted by Concomitant Psychosislike Symptoms.

Cassano P, Trinh NH, Chang T, Cusin C, Fisher L, Pedrelli P, Nyer M, Kim DJ, Alpert J, Mischoulon D.

J Nerv Ment Dis. 2015 Oct;203(10):769-73. doi: 10.1097/NMD.0000000000000365.

PMID:
26356091
7.

Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy.

Morries LD, Cassano P, Henderson TA.

Neuropsychiatr Dis Treat. 2015 Aug 20;11:2159-75. doi: 10.2147/NDT.S65809. eCollection 2015. Review.

8.

Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos.

Cassano P, Chang T, Trinh NH, Baer L, Fava M, Mischoulon D.

J Affect Disord. 2013 Sep 5;150(2):578-84. doi: 10.1016/j.jad.2013.02.012. Epub 2013 Mar 13.

9.

Major depressive disorder with psychosis-like symptoms among Latinos.

Cassano P, Fava M, Mischoulon D.

Psychiatr Serv. 2012;63(5):482-7. doi: 10.1176/appi.ps.201100271. Review.

PMID:
22422016
10.

Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia.

Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Pini S, Cassano P, Daneluzzo E, De Peri L, Stratta P, Brunetti A, Maj M.

Schizophr Bull. 2008 Mar;34(2):393-401. Epub 2007 Aug 28.

11.

Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities.

Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, Nierenberg AA, Fava M.

J Nerv Ment Dis. 2007 Feb;195(2):175-8.

PMID:
17299307
12.
13.

Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.

Davis LL, Frazier E, Husain MM, Warden D, Trivedi M, Fava M, Cassano P, McGrath PJ, Balasubramani GK, Wisniewski SR, Rush AJ.

Am J Addict. 2006 Jul-Aug;15(4):278-85.

PMID:
16867922
14.

Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.

Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M.

Psychother Psychosom. 2005;74(6):362-5.

PMID:
16244512
15.

Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment.

Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M.

Neuropsychobiology. 2005;52(2):83-9. Epub 2005 Jul 19.

PMID:
16037677
16.

Ropinirole in treatment-resistant depression: a 16-week pilot study.

Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB.

Can J Psychiatry. 2005 May;50(6):357-60.

PMID:
15999953
17.

Depression and renal disease.

Tossani E, Cassano P, Fava M.

Semin Dial. 2005 Mar-Apr;18(2):73-81. Review.

PMID:
15771649
18.

Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.

Davis LL, Rush JA, Wisniewski SR, Rice K, Cassano P, Jewell ME, Biggs MM, Shores-Wilson K, Balasubramani GK, Husain MM, Quitkin FM, McGrath PJ.

Compr Psychiatry. 2005 Mar-Apr;46(2):81-9.

PMID:
15723023
19.

COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study.

Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M.

Schizophr Res. 2005 Feb 1;73(1):27-30.

PMID:
15567073
20.

Pramipexole in treatment-resistant depression: an extended follow-up.

Cassano P, Lattanzi L, Soldani F, Navari S, Battistini G, Gemignani A, Cassano GB.

Depress Anxiety. 2004;20(3):131-8.

PMID:
15549689

Supplemental Content

Loading ...
Support Center